TransCode Therapeutics In...

AI Score

0

Unlock

3.35
0.17 (5.35%)
At close: Jan 14, 2025, 3:59 PM
3.50
4.33%
Pre-market Jan 15, 2025, 04:14 AM EST
undefined%
Bid 3.2
Market Cap 2.34M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 5571.72
PE Ratio (ttm) 0
Forward PE n/a
Analyst Strong Buy
Ask 3.5
Volume 161,929
Avg. Volume (20D) 58,505
Open 3.50
Previous Close 3.18
Day's Range 3.15 - 3.50
52-Week Range 2.66 - 152.79
Beta undefined

About RNAZ

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 8, 2021
Employees 10
Stock Exchange NASDAQ
Ticker Symbol RNAZ

Analyst Forecast

According to 1 analyst ratings, the average rating for RNAZ stock is "Strong Buy." The 12-month stock price forecast is $20, which is an increase of 496.20% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 day ago · Source
+5.66%
TransCode Therapeutics shares are trading higher a... Unlock content with Pro Subscription
1 month ago · Source
-18.64%
TransCode Therapeutics shares are trading lower after the company announced a 1-for-33 reverse stock split.